Associated Papers
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.
Jentus MM et al.
Pathology International, 2026
KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
Mondal K et al.
Cells, 2024
PROMER technology: A new real-time PCR tool enabling multiplex detection of point mutation with high specificity and sensitivity.
Nam H et al.
Biology Methods & Protocols, 2024
Pathogenic signal peptide variants in the human genome.
Gutierrez Guarnizo SA et al.
Nar Genomics and Bioinformatics, 2023
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts.
Rosen JC et al.
Translational Oncology, 2021
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Szlosarek PW et al.
Cancer Medicine, 2021
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience.
Burns EA et al.
Journal of Thoracic Disease, 2021
Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer.
Shen M et al.
Frontiers in Oncology, 2021
Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A et al.
Diagnostic Pathology, 2019
ALK immunohistochemistry is highly sensitive and specific for the detection of ALK translocated lung adenocarcinomas: lessons from an audit of lung cancer molecular testing.
Kheng YC et al.
The Journal of the Royal College of Physicians of Edinburgh, 2018
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL et al.
Plos One, 2018
Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2016
Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
Zhang Q et al.
Cancer Chemotherapy and Pharmacology, 2016
EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features.
Jia X et al.
Contemporary Oncology (poznan, Poland), 2015
Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.
Su J et al.
Chinese Journal of Cancer, 2014
Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.
Alsdorf WH et al.
Experimental and Molecular Pathology, 2013
Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas.
Dai Z et al.
Molecular Cytogenetics, 2012